Brief: Urogen Pharma Plans To Initiate Phase 3 Study In 2024
17/01/2024 13:18
Jan 17 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN SECURES EXCLUSIVE LICENSE FROM MEDAC GMBH TO
DEVELOP A
NEXT-GENERATION NOVEL MITOMYCIN-BASED FORMULATION FOR UROTHELIAL
CANCERS
* UROGEN PHARMA LTD - PLANS TO INITIATE A PHASE 3 STUDY IN
2024 TO
EXPLORE SAFETY AND EFFICACY OF UGN-103 IN LG-IR-NMIBC
Source text for Eikon: ID:nBw2JS4X0a
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors